ArticleOncogene2015

Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer.

A Mavrou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.